Addressing the challenges of the clinical application of pharmacogenetic testing - PubMed (original) (raw)

Review

Addressing the challenges of the clinical application of pharmacogenetic testing

O N Ikediobi et al. Clin Pharmacol Ther. 2009 Jul.

Abstract

Pharmacogenomics aims to use molecular genetic markers to predict treatment outcome. Indeed, within the past decade there has been a rapid emergence of pharmacogenetic tests to aid clinicians in predicting efficacy or toxicity for some drugs. Despite this major advance in therapeutic drug management, there remain challenges to the appropriate use of pharmacogenetic tests. We discuss UGT1A1 pharmacogenetic testing to illustrate the knowledge gaps impeding widespread use of pharmacogenetic tests in the clinical setting.

PubMed Disclaimer

References

    1. Pollack A. Patient's DNA may be signal to tailor medication. The New York Times. 2008 December 29;
    1. Table of valid genomic biomarkers in the context of approved drug labels. U.S. Food and Drug Administration. [January 26, 2009]. http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm.
    1. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A. 1998;95:8170–8174. - PMC - PubMed
    1. Strassburg CP. Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics. 2008;9:703–715. - PubMed
    1. Ando Y, et al. Polymorphisms of UDP-glucuronosyltransferase gene and Irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60:6921–6926. - PubMed

Publication types

MeSH terms

LinkOut - more resources